# Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Source: https://onco.cc/trials/nct04464226/  
OnCo record `nct04464226` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Darolutamide in advanced solid tumours, run by Bayer, active and no longer recruiting.

## Summary

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer is a phase 3 interventional study registered as NCT04464226 by Bayer, with 402 participants enrolled, started 2020-10-20 and due to reach its primary completion in 2028-06-26. Interventions recorded: Darolutamide (Nubeqa, BAY1841788).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04464226
- Phase: 3
- Setting: An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies
- Sponsor: Bayer
- Enrolled: 402

## Sources

- ClinicalTrials.gov NCT04464226: https://clinicaltrials.gov/study/NCT04464226

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Darolutamide](https://onco.cc/drugs/darolutamide/)
- companies: [Bayer](https://onco.cc/companies/bayer/)

---
JSON: https://onco.cc/api/v1/entities/nct04464226.json